Buch, Englisch, 168 Seiten, Format (B × H): 156 mm x 234 mm, Gewicht: 245 g
Market Access and Funding
Buch, Englisch, 168 Seiten, Format (B × H): 156 mm x 234 mm, Gewicht: 245 g
Reihe: Pharmaceuticals, Health Economics and Market Access
ISBN: 978-0-367-40809-1
Verlag: CRC Press
Key Features:
- Describes the potential change of treatment paradigm and the specificity of cell and gene therapies, including the gradual move from repeated treatment administration to one-time single administration with the potential to be definite cure
- Highlights the challenges at the HTA level
- Discusses the affordability of future cell and gene therapies and the possible challenges for health insurance systems
- Provides potential solutions to address these challenges and ensure patient access to innovation while maintaining the sustainability of healthcare systems
Zielgruppe
Academic, Postgraduate, Professional, and Professional Practice & Development
Autoren/Hrsg.
Fachgebiete
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
- Naturwissenschaften Chemie Chemie Allgemein
- Technische Wissenschaften Sonstige Technologien | Angewandte Technik Medizintechnik, Biomedizintechnik
- Naturwissenschaften Biowissenschaften Zellbiologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Medizintechnik, Biomedizintechnik, Medizinische Werkstoffe
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Pharmazie
- Wirtschaftswissenschaften Wirtschaftssektoren & Branchen Fertigungsindustrie Pharmaindustrie
Weitere Infos & Material
Chapter 1 Introduction to cell and gene therapies concepts and definitions in the US and EU. 1
Chapter 2 Cell and gene therapies: genuine products and potential for dramatic value. 19
Chapter 3 Cell and gene therapies: regulatory aspects in the US and EU. 31
Chapter 4 The need for new HTA reference case for cell and gene therapies. 59
Chapter 5 How to mitigate uncertainties and HTA risk-averse attitude?. 91
Chapter 6 Cell and gene therapies funding: challenges and solutions for patients’ access. 101
Chapter 7 Conclusion. 129